Nafoxidine - CAS 1845-11-0
Catalog number:
1845-11-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H31NO2
Molecular Weight:
425.56
COA:
Inquire
Targets:
Estrogen Receptor/ERR
Description:
Nafoxidine, a triphenylethylene nonsteroidal agent, is a partial estrogen antagonist.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
Clear, colourless to yellow liquid
Synonyms:
1-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine; 5-20-01-00210 (Beilstein Handbook Reference); BRN 1440873; Nafoxidina; Nafoxidina [INN-Spanish]; Nafoxidine; Nafoxidinum; Nafoxidinum [INN-Latin]; NSC 70735; UNII-4RIY10WM82
MSDS:
Inquire
Boiling Point:
241.00 to 242.00 ºC at 760.00 mmHg (est)
InChIKey:
JEYWNNAZDLFBFF-UHFFFAOYSA-N
InChI:
1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
Canonical SMILES:
COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5
1.Tracing the origins of COX-2 inhibitors' structures.
Lednicer D1. Curr Med Chem. 2002 Aug;9(15):1457-61.
This review traces the origins of the chemical structure of the cyclooxygenase inhibitors celecoxib and rofecoxib. Early results from the search for non-steroid estrogens led to the triaryl-ethylenes such as chlortrianisene. A congener that incorporated a water-solubilizing basic ether grouping unexpectedly led to an estrogen antagonist and eventually the drug clomiphene. Elaboration of the structure gave the widely used drug used to treat breast cancer tamoxifen. Cyclized analogues such as nafoxidine showed equivalent activity but were not pursued. Later elaboration of those structures gave the now-marketed drug raloxifene. An indole analogue, indoxole, (2,3-dianisylindole) surprisingly showed anti-inflammatory activity. An analogue program designed to reduce photosensitivity from that compound eventually led to the discovery that the indole ring could be replaced by a simple thiazole, This resulted in the experimental cyclooxygenase inhibitor itazagrel.
2.Multifactorial activities of nonsteroidal antiestrogens against leukemia.
Hayon T1, Atlas L, Levy E, Dvilansky A, Shpilberg O, Nathan I. Cancer Detect Prev. 2003;27(5):389-96.
The antileukemic activity of nonsteroidal antiestrogens was investigated. Tamoxifen, clomiphene and nafoxidine caused a decrease in viability of the estrogen receptor-negative T-lymphoblastic leukemia cell line CCRF/CEM, nafoxidine being the most active. A combination of clomiphene and genistein resulted in a synergistic cytotoxic effect when applied to Molt-3, another T-lymphblastic leukemic cell line. The antiestrogens arrested the cells at G(0)/G(1) phase and induced apoptosis. Using the CCRF/VCR(1000) cell line, which is resistant to vincristine, it was observed that the effect of nafoxidine on modulating drug resistance was manifested at a lower concentration than that causing a direct cytotoxic effect. Nafoxidine inhibited the Pgp pump activity as measured by rhodamine 123 efflux. Combination with verapamil was found to be more effective in abrogating the pump activity. This study points to the multifactorial activities of nonsteroidal antiestrogens against lymphoblastic leukemia and implies their potential use in clinical treatment as antileukemic drugs.
3.Thermotropic liquid crystalline drugs.
Bunjes H1, Rades T. J Pharm Pharmacol. 2005 Jul;57(7):807-16.
Crystalline solids are characterized by long-range positional and orientational order in three dimensions, whereas amorphous liquids lack long-range order in any dimension. Liquid crystals (mesophases) show structural, mechanical and optical properties intermediate to those of crystalline solids and the amorphous, liquid state of matter. There are two principle types of liquid crystals: thermotropic liquid crystals (TLCs) and lyotropic liquid crystals (LLCs). TLCs can be formed by heating a crystalline solid or by cooling an isotropic melt of a TLC-forming molecule (mesogen). In the first part of this review the types of liquid crystals are defined and classified and the structural properties of mesogens are explained. In the second part, ten case studies of thermotropic mesomorphous drugs and pharmaceutically relevant molecules (arsphenamine, nafoxidine hydrochloride, L-660711, palmitoyl propranolol hydrochloride, penbutolol sulfate, itraconazole hydrochloride, fenoprofen sodium, fenoprofen calcium, ciclosporin and cholesteryl esters) are presented and their thermotropic mesomorphism is described.
4.Kinetic analysis of estrogen receptor/ligand interactions.
Rich RL1, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, Hensley P, Myszka DG. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8562-7. Epub 2002 Jun 19.
Surface plasmon resonance biosensor technology was used to directly measure the binding interactions of small molecules to the ligand-binding domain of human estrogen receptor. In a screening mode, specific ligands of the receptor were easily discerned from nonligands. In a high-resolution mode, the association and dissociation phase binding responses were shown to be reproducible and could be fit globally to a simple interaction model to extract reaction rate constants. On average, antagonist ligands (such as tamoxifen and nafoxidine) were observed to bind to the receptor with association rates that were 500-fold slower than agonists (such as estriol and beta-estradiol). This finding is consistent with these antagonists binding to an altered conformation of the receptor. The biosensor assay also could identify subtle differences in how the same ligand interacted with two different isoforms of the receptor (alpha and beta). The biosensor's ability to determine kinetic rate constants for small molecule/protein interactions provides unique opportunities to understand the mechanisms associated with complex formation as well as new information to drive the optimization of drug candidates.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Estrogen Receptor/ERR Products


CAS 82640-04-8 Raloxifene HCl

Raloxifene HCl
(CAS: 82640-04-8)

Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It ...

Phenethipylone
(CAS: 63676-25-5)

Phenethipylone is a selective estrogen receptor modulator. It is a raloxifene analog.

CAS 343248-86-2 ERA63

ERA63
(CAS: 343248-86-2)

A selective agonist of estrogen receptor α

CAS 7280-37-7 Estropipate

Estropipate
(CAS: 7280-37-7)

Estropipate is an estrogen receptor agonist used in post-menopausal women for hormonal replacement therapy, with benefits to improved cognition and prevention o...

CAS 190791-29-8 Lasofoxifene tartrate

Lasofoxifene tartrate
(CAS: 190791-29-8)

Lasofoxifene tartrate is the tartrate salt form of Lasofoxifene. Lasofoxifene is a third-generation selective estrogen receptor modulators (SERMs).

CAS 53-16-7 Estrone

Estrone
(CAS: 53-16-7)

Estrone is one of the three naturally occurring estrogens, the others being estradiol and estriol. Estrone is synthesized from androstenedione by the aromatase ...

CAS 89778-27-8 PF-03758309

PF-03758309
(CAS: 89778-27-8)

PF-03758309 is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 with IC50 of 1.3 nM.

CAS 54965-24-1 Tamoxifen Citrate

Tamoxifen Citrate
(CAS: 54965-24-1)

Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding, leading to a reduction in DNA synthesis and cellular ...

CAS 1428-67-7 Diarylpropionitrile

Diarylpropionitrile
(CAS: 1428-67-7)

Diarylpropionitrile, also called as DPN, is a selective agonist of estrogen receptor β (ERβ) with a 70-fold higher relative binding affinity for ERβ(18%) versus...

CAS 725247-18-7 XCT 790

XCT 790
(CAS: 725247-18-7)

XCT-790 is a potent, selective ERRα antagonist/inverse agonist (IC50 = ~400 nM), displaying no antagonist activity at ERRγ or ERα at concentrations below 10 μM.

CAS 72-33-3 Mestranol

Mestranol
(CAS: 72-33-3)

Mestranol is the 3-methyl ether of ethinylestradiol. It was the estrogen used in many of the first oral contraceptives.

Endoxifen E-isomer hydrochloride
(CAS: 1197194-61-8)

The hydrochloride salt form of E-isomer of Endoxifen which is a significant metamolite of Tamoxifen, could be a regulator of estrogen receptor and could be effe...

Elacestrant S enantiomer dihydrochloride

Elacestrant S enantiomer dihydrochloride is an low activity enantiomer of elacestrant dihydrochloride. Elacestrant, also referred to RAD1901, is a selective and...

CAS 57-63-6 Ethinyl Estradiol

Ethinyl Estradiol
(CAS: 57-63-6)

Ethinyl Estradiol is a derivative of 17β-estradiol (E2), the major endogenous estrogen in humans. EE2 is an orally bioactive estrogen used in many formulations ...

CAS 440122-66-7 WAY-200070

WAY-200070
(CAS: 440122-66-7)

WAY-200070 is a selective estrogen receptor β (ERRβ) agonist (IC50= 2.3 nM) that exhibit 68-fold selectivity over ERα (EC50= 155 nM for ERα).

BHPI
(CAS: 56632-39-4)

BHPI is an antagonist of estrogen receptor α (ERα), for it elicits sustained ERα-dependent activation of the endoplasmic reticulum (EnR) stress sensor.

CAS 50-27-1 Estriol

Estriol
(CAS: 50-27-1)

Estriol is a metabolite of 17β-estradiol with much lower biological activity. It is the primary estrogen found in the urine. Large quantities of estriol and est...

CAS 198481-32-2 Bazedoxifene

Bazedoxifene
(CAS: 198481-32-2)

Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.

CAS 95167-41-2 DY131

DY131
(CAS: 95167-41-2)

DY131 is a novel selective agonist of ERRβ and ERRγ, which displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM. It could potentiate the...

CAS 1847-63-8 Nafoxidine HCl

Nafoxidine HCl
(CAS: 1847-63-8)

Nafoxidine HCl is the hydrochloride salt of nafoxidine. Nafoxidine, structurally related to Tamoxifen, is a non-steroidal partial estrogen antagonist.

Chemical Structure

CAS 1845-11-0 Nafoxidine

Quick Inquiry

Verification code

Featured Items